$KRRO

FORMELA JEAN FRANCOIS sold $34K of KRRO (indirect holdings)

FORMELA JEAN FRANCOIS sold 2,441 indirectly-held shares of Korro Bio, Inc. (KRRO) at $13.95 on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FORMELA JEAN FRANCOIS
Published Jun 1, 2026, 9:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KRRO
Neutral
high confidence
Mentioned
$KRRO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRRONeutralLow
01

Why it matters

Insider sales under 10b5-1 plans are generally viewed as less informative than discretionary sales, so the event is more sentiment/positioning-related than fundamental.

02

Market read

A routine 10b5-1 insider sale disclosure for KRRO with limited expected impact beyond minor sentiment.

03

What to watch

The sale size ($34k) is relatively small versus typical biotech market caps, and the indirect ownership detail may further reduce signal strength.

Relevance 6/10Novelty 3/10Timing: Filed June 1; sale executed May 28 under a 10b5-1 plan.

Background

The article is an SEC Form 4 insider transaction disclosure for Korro Bio, Inc.

Company-level read

Ticker impact

$KRRONeutralHigh confidence
Context

Korro Bio director sold 2,441 shares in an open-market transaction under a pre-arranged 10b5-1 plan on May 28.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 insider sale and explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretive signal.

Market effects

No clear sector read-through from a single 10b5-1 director sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with weaker near-term expectations; traders may monitor for follow-on sales.

Key entities

  • Korro Bio, Inc.

    Subject of the insider transaction disclosure; director sold shares under a pre-arranged 10b5-1 plan.

  • FORMELA JEAN FRANCOIS

    Director who executed the open-market sale disclosed on Form 4.

Related articles

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria